Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data
February 3, 2017 6:53 AM ESTBMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following positive Repatha CV outcomes data
Analyst M. Ian Somaiya commented, "Addition of CV outcomes data to the Repatha label and launch of erenumab for migraine... More
Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance
February 2, 2017 4:23 PM ESTAmgen (NASDAQ: AMGN) reported Q4 EPS of $2.89, $0.10 better than the analyst estimate of $2.79. Revenue for the quarter came in at $5.97 billion versus the consensus estimate of $5.74 billion.
GUIDANCE:
Amgen sees FY2017 EPS of $11.80-$12.60, versus the consensus of $12.44. Amgen sees... More
